Glycomic Therapeutics Market Global Analysis & Forecast 2028
The glycomic therapeutics market is expected to grow from US$ 99,021.46 million in 2021 to US$ 257,578.79 million in 2028; it is estimated to grow with a CAGR of 15.8% from 2022 to 2028.
The report highlights prevailing trends and factors driving the market growth. Glycomics focuses on the structures and functions of complex carbohydrates, as found in glycoproteins, glycolipids, and glycosaminoglycans. Glycans are responsible for much of the structural variation in biological systems, and their representation on cell surfaces is commonly called the “glycome”. These glycans are present in many areas of the microbiome, including cell surfaces and proteins, and can be incredibly complex. Microbial glycomics is poised to revolutionize disease diagnosis, cancer detection, personalized medicine, antimicrobial vaccine, and drug discovery. As therapeutic agents, glycan-integrated nanomaterials can be used as a vaccine against viral and bacterial infections and cancer cells.
The report offers insights and in-depth analysis of the global glycomic therapeutics market, emphasizing various parameters, including market trends, technological advancements, market dynamics, and competitive landscape analysis of global leading market players. It also includes the impact of the COVID-19 pandemic on the market across all regions. The overall impact of the COVID-19 pandemic on the glycomic therapeutics market was mixed; hence, the market is still gaining traction and is expected to grow in the coming years. The health care systems were overburdened, and the delivery of medical care to all patients became a challenge. In addition, the biotechnology industry faced the undesirable impact of the pandemic. During the COVID-19 pandemic, medical device companies found difficulties managing their operations. Many companies of glycomic therapeutics had their business operations in the US, and the pandemic severely affected several businesses. However, after the pandemic restrictions normalized, the volume of surgical procedures returned to normal levels. Gradually hospitals resumed elective procedures as the COVID-19 recovery rate was increasing. The demand for glycan-based drugs in medical therapeutics and vaccine development applications has also increased.
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Glycomic Therapeutics Market: Strategic Insights
Glycomic Therapeutics Market
-
CAGR (2021 - 2028)
15.8%
-
Market Size 2021
US$ 99.02 Billion
-
Market Size 2028
US$ 257.58 Billion
Market Dynamics
GROWTH DRIVERS
- XXXXXXX
- XXXXXXX
- XXXXXXX
FUTURE TRENDS
- XXXXXXX
- XXXXXXX
- XXXXXXX
OPPORTUNITIES
- XXXXXXX
- XXXXXXX
- XXXXXXX
Key Players
- Intellihep Ltd
- Protalix Biotherapeutics
- BioMarin Pharmaceutical Inc
- Genzyme Corporation Sanofi
- Halozyme Therapeutics Inc
- Bayer AG
- Alzheon Inc
- GlycoMar
- GlaxoSmithKline plc
Regional Overview
- North America
- Europe
- Asia-Pacific
- South and Central America
- Middle East and Africa
Market Segmentation
Class
- Isolated and Synthetic
Structures
- Glycoproteins
- Targeting Sialic Acid
- Proteoglycans
- Targeting Glycosaminoglycans
- Glycosylphosphatidylinositol
Indications
- Thrombosis & Chemoprophylaxis
- Anaemia
- Anti-Adhesive & Anti-Inflammatory
- Cataracts
- Gaucher?s Disease
- MPS-1 & IV
- Cancer
- Alzheimer?s Disease
- Influenza Type A & B
- Others
Mode of Action
- Inhibits Neuraminidase
- Inhibits Heparanase and Selectins and Blocks Interactions Between Growth Factors and Heparan Sulfate
- Erythropoietin & Enzyme Replacement Therapy
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Glycomic Therapeutics Market: Strategic Insights
-
CAGR (2021 - 2028)15.8% -
Market Size 2021
US$ 99.02 Billion -
Market Size 2028
US$ 257.58 Billion
Market Dynamics
- XXXXXXX
- XXXXXXX
- XXXXXXX
- XXXXXXX
- XXXXXXX
- XXXXXXX
- XXXXXXX
- XXXXXXX
- XXXXXXX
Key Players
- Intellihep Ltd
- Protalix Biotherapeutics
- BioMarin Pharmaceutical Inc
- Genzyme Corporation Sanofi
- Halozyme Therapeutics Inc
- Bayer AG
- Alzheon Inc
- GlycoMar
- GlaxoSmithKline plc
Regional Overview
- North America
- Europe
- Asia-Pacific
- South and Central America
- Middle East and Africa
Market Segmentation
- Isolated and Synthetic
- Glycoproteins
- Targeting Sialic Acid
- Proteoglycans
- Targeting Glycosaminoglycans
- Glycosylphosphatidylinositol
- Thrombosis & Chemoprophylaxis
- Anaemia
- Anti-Adhesive & Anti-Inflammatory
- Cataracts
- Gaucher?s Disease
- MPS-1 & IV
- Cancer
- Alzheimer?s Disease
- Influenza Type A & B
- Others
- Inhibits Neuraminidase
- Inhibits Heparanase and Selectins and Blocks Interactions Between Growth Factors and Heparan Sulfate
- Erythropoietin & Enzyme Replacement Therapy
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
Geography-Based Insights
By geography, the global glycomic therapeutics market is segmented into North America (the US, Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific), the Middle East & Africa (the UAE, Saudi Arabia, South Africa, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).
Market Insights
Increasing Research and Development in the Field of Glycomic Therapeutics
Glycans are exceedingly complex and found in many areas of the microbiome components, such as proteins and cell surfaces. Researchers and players are actively involved in the glycomics industry and are constantly focusing on technological developments to offer better alternatives to conventional techniques. A few examples of research & development in the glycomic therapeutics market are mentioned below:
- In February 2022, the National Science Foundation (NSF) awarded ~US$ 23 million to a new multi-university partnership, jointly led by Virginia Tech and the University of Georgia, 2020, to accelerate glycomaterials research in the US. This partnership brought together top scientists and engineers from these institutions, along with Brandeis University, Rensselaer Polytechnic Institute, and the University of North Carolina at Chapel Hill, to establish a national glycomaterials research center.
- In March 2022, Palleon Pharmaceuticals, a company pioneering the field of glycol-immunology to treat cancer and inflammatory diseases, announced the dosing of the first patient in the company’s Phase 1/2 study of E-602 in patients suffering from advanced cancers. The study, called GLIMMER-01 (Glycan-Immune Regulation), is the first clinical study of Palleon’s novel approach to cancer immunotherapy, which targets immunosuppressive sialoglycans.
- In April 2022, CPTAC glycoproteomic researchers developed "Peptide-First" multi-attribute glycan identification method.
- In March 2022, Japanese researchers uncovered the precise mechanism of a beta-1,2-glucan-associated enzyme to provide new information on complicated sugar metabolism. A team of researchers from Niigata University and Tokyo University of Science identified the structure and function of a new enzyme with glycosyltransferase activity. The findings of this investigation were made public on January 19, 2022, and were printed in the Journal of Biological Chemistry, Volume 298, Issue 3.
- According to a study published in February 2022 by researchers at the University of Copenhagen's Center for Glycomics, Heparin can now be produced without using animals through glycomics studies.
- In February 2022, GlycoMIP, a national research hub focused on glycomaterials research and led jointly by Virginia Tech and the University of Georgia, celebrated the grand opening of its national user facility with ribbon-cutting ceremonies at both universities. GlycoMIP will address nationwide bottlenecks in glycomaterial synthesis, computer modeling, material characterization, and knowledge sharing through ground-breaking research and a unique national user facility that will provide critical tools and services to the scientific community.
Such advancements in the field of glycomics propel the glycomic therapeutics market growth significantly.
Class-Based Insights
Based on the class, the glycomic therapeutics market is bifurcated into isolated and synthetic. In 2021, the synthetic segment accounted for a larger market share. However, the isolated segment is expected to register a higher CAGR of 16.3% during the forecast period.
Structure-Based Insights
Based on structures, the glycomic therapeutics market is segmented into glycoproteins, targeting sialic acid, proteoglycans, targeting glycosaminoglcans, glycophosphatidylinositol (GPI)-anchored proteins & heparin based glycans, targeting glycosphingolipids, and others. The glycoproteins segment held the largest market share in 2021. However, the targeting sialic acid segment is anticipated to register the highest CAGR during the forecast period.
Indication-Based Insights
Based on indication, the glycomic therapeutics market is segmented into thrombosis & chemoprophylaxis, anemia, anti-adhesive & anti-inflammatory, cataract, Gaucher’s diseases, MPS-1 & IV, cancer, Alzheimer’s disease, influenza type A & B, and others. The influenza type A & B segment held the largest market share in 2021, and it is expected to continue a similar trend during the forecast period.
Glycomic Therapeutics Market Report Scope
Report Attribute
Details
Market size in 2021
US$ 99.02 Billion
Market Size by 2028
US$ 257.58 Billion
Global CAGR (2021 - 2028)
15.8%
Historical Data
2019-2020
Forecast period
2022-2028
Segments Covered
By Class - Isolated and Synthetic
By Structures - Glycoproteins
- Targeting Sialic Acid
- Proteoglycans
- Targeting Glycosaminoglycans
- Glycosylphosphatidylinositol
By Indications - Thrombosis & Chemoprophylaxis
- Anaemia
- Anti-Adhesive & Anti-Inflammatory
- Cataracts
- Gaucher?s Disease
- MPS-1 & IV
- Cancer
- Alzheimer?s Disease
- Influenza Type A & B
- Others
By Mode of Action - Inhibits Neuraminidase
- Inhibits Heparanase and Selectins and Blocks Interactions Between Growth Factors and Heparan Sulfate
- Erythropoietin & Enzyme Replacement Therapy
Regions and Countries Covered
North America - US
- Canada
- Mexico
Europe - UK
- Germany
- France
- Russia
- Italy
- Rest of Europe
Asia-Pacific - China
- India
- Japan
- Australia
- Rest of Asia-Pacific
South and Central America - Brazil
- Argentina
- Rest of South and Central America
Middle East and Africa - South Africa
- Saudi Arabia
- UAE
- Rest of Middle East and Africa
Market leaders and key company profiles
- Intellihep Ltd
- Protalix Biotherapeutics
- BioMarin Pharmaceutical Inc
- Genzyme Corporation Sanofi
- Halozyme Therapeutics Inc
- Bayer AG
- Alzheon Inc
- GlycoMar
- GlaxoSmithKline plc
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
Report Attribute | Details |
---|---|
Market size in 2021 | US$ 99.02 Billion |
Market Size by 2028 | US$ 257.58 Billion |
Global CAGR (2021 - 2028) | 15.8% |
Historical Data | 2019-2020 |
Forecast period | 2022-2028 |
Segments Covered |
By Class
|
Regions and Countries Covered | North America
|
Market leaders and key company profiles |
|
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
Mode of Action-Based Insights
Based on mode of action, the glycomic therapeutics market is segmented into inhibits neuraminidase; inhibits heparanase and selectins and blocks interactions between growth factors and heparan sulfate; erythropoietin & enzyme replacement therapy (ERT); tissue plasminogen activator; inhibits glucosylceramide synthase; interleukin 1, 2 & 3; beta & gamma interferons; and others. In 2021, the erythropoietin & enzyme replacement therapy (ERT) segment held the largest share of the market. However, the inhibits neuraminidase segment is expected to register the highest CAGR during the forecast period.
Intellihep Ltd; Protalix Biotherapeutics; BioMarin Pharmaceutical Inc.; Genzyme Corporation (Sanofi); Halozyme Therapeutics, Inc.; Bayer AG; Alzheon, Inc.; GlycoMar; GlaxoSmithKline plc.; and F. Hoffmann-La Roche Ltd are among the leading players operating in the glycomic therapeutics market. These companies have been implementing various strategies that have helped their growth, resulting in several developments in the market.
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
Class, Structures, Indications, and Mode of Action
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
Argentina, Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, Saudi Arabia, South Africa, South Korea, Spain, United Arab Emirates, United Kingdom, United States
Frequently Asked Questions
The growth of the market is attributed to wide application in various disorders followed by the development of new treatment processes, increasing research and development in the field of glycomic therapeutics, and expanding R&D investments and rising use of glycomics in various diseases leading to development of new treatment processes.
Based on geography, the APAC region is anticipated to witness the highest CAGR in glycomic therapeutics market during the forecast period.
The synthetic segment under class segment held the largest market share in 2021.
The glycomic therapeutics market majorly consists of the players such as Intellihep Ltd; Protalix Biotherapeutics; BioMarin Pharmaceutical Inc.; Genzyme Corporation (Sanofi); Halozyme Therapeutics, Inc.; Bayer AG; Alzheon, Inc.; GlycoMar; GlaxoSmithKline plc.; and F. Hoffmann-La Roche Ltd.
The List of Companies - Glycomic Therapeutics Market
- Intellihep Ltd
- Protalix Biotherapeutics
- BioMarin Pharmaceutical Inc.
- Genzyme Corporation (Sanofi)
- Halozyme Therapeutics, Inc.
- Bayer AG
- Alzheon, Inc.
- GlycoMar
- GlaxoSmithKline plc.
- F. Hoffmann-La Roche Ltd